QuidelOrtho Corporation

$ 13.67 4.11 %

QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.

CEO: Brian J. Blaser - https://www.quidelortho.com

Price objectif

$12.25 -10.39 %

Recommandation

Hold

DCF

$ -45.17

Loading data...

QDEL vs S&P500

Loading data...

No data available.

Quick ratio

0.80

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

-0.77

may indicate that the company is undervalued or has poor growth prospects.

EPS

-17.85

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-56.31 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-19.88 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

5.55

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

1.55

means it relies more on debt, which can increase financial risk.

Free cash flow per share

-1.10

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
4 indicates moderate financial health
Altman score
-0.15 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.15 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.51 indicates a moderate level of debt, which is generally acceptable but may present some risk
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.